Also this year the Gianni Benzi Pharmacological Research Foundation has organised the Foresight Training Course entitled ‘EUROPE LEADS THE BEST MEDICINES SYSTEM FOR PATIENTS’, at its ninth edition now.
The Gianni Benzi Foundation is a non-profit Scientific Research Organization, founded in November 2007 to advance the legacy of Professor Gianni Benzi, a renowned scientist who devoted himself to supporting the set-up of the European Pharmaceutical System.
Foresight Training Courses are short-term international courses aimed at highly-specialised professional profiles in the different fields of Regulatory Sciences, that provide participants with valuable opportunities to share good practices in pharmacological research and drug development.
The Ninth Course was promoted in collaboration with the Master in “Regulatory Sciences – G. BENZI” (University of Pavia) and the TEDDY Network – European Network of Excellence for Paediatric Clinical Research and took place from October 27th to October 29th 2016, at Collegio Fratelli Cairoli (Pavia, Italy).
This 3-day meeting was aimed to provide a special acknowledgment to Prof Gianni Benzi for his significant contribution to the European Medicines System setting up and implementation with special reference to fields in which Gianni Benzi was particularly involved. Prof. Benzi was a medical doctor and a Professor who studied at the University of Pavia where he founded the School of Specialisation in Regulatory Disciplines (today Second level Master).
He believed that, when it concerns drugs, it is not enough to only consider the relationship between the Ministry and the Pharmas, but it is necessary to also consult universities, researchers, clinicians and patients.
The main topics of the Course were:
- EM(e)A scientific, economic and social role,
- Orphan and Innovative therapies,
- Paediatric Medicines,
- Evidence, risks and benefits from drug uses,
- Patients’ role and contribution.
As pointed out by the Professor Adriana Ceci, President of the Gianni Benzi Foundation, “the meeting has highlighted the great effort and commitment of the European Medicines Agency (EMA) to conduct research on innovative medicines, but at the same time the problems that the agency is facing after the Brexit”.
Here you can download the meeting brochure.